Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TPST files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTempest announces Senlang collaboration for in vivo CAR-T trial, reports $0.8M cash
Filed August 13, 2026 · Period ending August 13, 2026 · ~2 min read
Key Changes
-
high
Tempest partnered with Senlang Biotechnology to advance TPST-4003, a CD7-targeted in vivo CAR-T candidate, in an investigator-initiated trial enrolling ~10 patients with myasthenia gravis or multiple sclerosis in China; first patient dosing expected Q4 2026.
Exhibit 99.1 view on EDGAR → -
high
Cash and cash equivalents fell to $0.8 million at June 30, 2026 from $7.7 million at year-end 2025, driven by transaction costs from the February asset acquisition, partially offset by $1.7 million from a March private placement and $1.7 million from a Q2 warrant inducement.
Exhibit 99.1 view on EDGAR → -
high
Q2 2026 net loss was $5.2 million ($0.34 per share), down from $7.9 million ($2.07 per share) in Q2 2025; six-month R&D expenses fell to $1.9 million from $11.5 million year-over-year, but the company recorded $22.1 million in acquired in-process R&D expenses related to the February asset acquisition.
Exhibit 99.1 view on EDGAR → -
high
Partner Novatim reported 100% complete response rate among 15 CAR-T-naïve patients treated with TPST-2003 (dual CD19/BCMA CAR-T) across two trials, with no Grade ≥3 cytokine release syndrome or neurotoxicity in the REDEEM-1 trial and median progression-free survival of 23.1 months in a prior trial.
Exhibit 99.1 view on EDGAR → -
medium
Tempest appointed Drake Richey and John Yee, MD, MPH, as independent directors, adding corporate finance and therapeutic development expertise to the Board.
Exhibit 99.1 view on EDGAR →
Summary
Tempest Therapeutics disclosed Q2 2026 financial results and announced a strategic collaboration with Hebei Senlang Biotechnology to advance TPST-4003, a CD7-targeted in vivo CAR-T candidate, in an investigator-initiated trial in China. The company's cash position is a concern for retail holders. Cash and cash equivalents fell to $0.8 million at quarter-end from $7.7 million at year-end 2025, driven by transaction costs from the February asset acquisition.
While the company raised $1.7 million in a March private placement and another $1.7 million from a warrant inducement in Q2, the low cash balance raises questions about runway and the need for additional financing to support the Senlang collaboration and other pipeline programs. Q2 net loss was $5.2 million, down from $7.9 million in the prior-year quarter, and six-month R&D expenses fell sharply to $1.9 million from $11.5 million, reflecting re-prioritization following the asset acquisition. However, the company recorded $22.1 million in acquired in-process R&D expenses related to the acquisition. On the clinical front, partner Novatim reported positive interim results for TPST-2003, a dual CD19/BCMA CAR-T therapy, showing 100% complete response among 15 CAR-T-naïve patients and a favorable safety profile with no Grade 3 or higher cytokine release syndrome or neurotoxicity. The company also appointed two independent directors with corporate finance and therapeutic development expertise.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Tempest Therapeutics announced Q2 2026 financial results and business highlights via press release.
Added in current filing · verify on EDGAR →
On [August 13], 2026, Tempest Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and other business highlights.
The company disclosed its financial results for the quarter ended June 30, 2026 through a press release. The 8-K body does not contain the actual financial figures or business highlights; those details are in the attached Exhibit 99.1 press release, which was not provided in the filing text.
Event · Exhibit 99.1
Tempest reports Q2 2026 results, announces Senlang collaboration for TPST-4003 in vivo CAR-T trial, and appoints two new board members.
Added in current filing · view on EDGAR → · paraphrased
Net loss and net loss per share for the quarter were $5.2 million and $0.34, respectively, compared to $7.9 million and $2.07, respectively, for the three months ended June 30, 2025. ... Tempest ended the quarter with $0.8 million in cash and cash equivalents, compared to $7.7 million on December 31, 2025.
Tempest reported a Q2 2026 net loss of $5.2 million ($0.34 per share), down from $7.9 million ($2.07 per share) in Q2 2025. Cash and cash equivalents fell to $0.8 million at quarter-end from $7.7 million at year-end 2025, driven by transaction costs from the February 2026 asset acquisition, partially offset by $1.7 million from a March private placement and $1.7 million from a warrant inducement in Q2.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 13, 2026 · How we verify